12:00 AM
 | 
Feb 07, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Necitumumab: Phase III data

Bristol-Myers and partner Eli Lilly stopped enrollment in the open-label, international Phase III INSPIRE trial of necitumumab as first-line treatment of non-squamous NSCLC after an independent DMC reported safety concerns related to thromboembolism in patients receiving the compound. The trial, which enrolled about 600 of a planned 947 patients, is evaluating cisplatin and ...

Read the full 246 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >